Vikas P. Sukhatme will step down as dean of Emory School of Medicine and chief academic officer of Emory Healthcare in March 2023. He will remain at Emory as a full-time faculty member.
The U.S. new cases 7-day rolling average are 23.7 % LOWER than the 7-day rolling average one week ago and U.S. deaths due to coronavirus are now 7.7 %
LOWER than the rolling average one week ago. Today s posts include:
U.S. Coronavirus New Cases are 14,144
U.S. Coronavirus deaths are at 189
U.S. Coronavirus immunizations have been administered to 85.4 doses per 100 people.
The 7-day rolling average rate of growth of the pandemic shows new cases were little changed and deaths improved Not convinced COVID-19 developed naturally, need more open investigations: Dr Anthony Fauci
New information on Wuhan researchers illness furthers the debate on pandemic origins
by Tyler Durden
Saturday, May 22, 2021 - 09:00 PM
Last week, we reported that several increasingly desperate communities across India have been embracing a controversial (at least, in the US) strategy for trying to mitigate the fallout from the crisis. Communities have been doling out inexpensive anti-malaria drugs as a prophylactic against COVID-19, citing scant data showing it could help lower mortality and hospitalization rates - which is critical given India s nationwide shortage of hospital beds and oxygen to sustain seriously ill patients.
The drug in question, ivermectin, is in some ways similar to hydroxychloroquine, which also showed some evidence of being an effective prophylactic to protect the most vulnerable against COVID-19 (President Trump memorably informed the press that he was taking it daily at one point). But since India is mostly cut off from adequate supplies of vaccines and therapeutics like Gilead s remdesivir (which studies have shown isn t all that effect
Professor Vikas P. Sukhatme, MD, ScD: Existing affordable drugs like Ivermectin could rapidly reduce Covid-19 cases and deaths in India
Posted on
The COVID-19 humanitarian calamity unfolding in India is on a scale not seen in this pandemic. This is an extraordinary situation – and it may benefit from an extraordinary response.
There exist affordable, readily available and minimally toxic drugs approved for non-COVID-19 use which show remarkable promise in preventing or treating the new coronavirus. Deploying these drugs in India is likely to rapidly reduce the number of COVID-19 patients, reduce the number requiring hospitalization, supplemental oxygen and intensive care and improve outcomes in hospitalized patients.